Philips Joins Forces with the American Telemedicine Association to Further Commitment to Telehealth

June 19, 2020

Philips recently announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute, and home care settings.

Philips said the continued collaboration spotlights the growing adoption and momentum in telehealth amidst COVID-19, and the need to convey the exponential shift to telehealth capabilities.

The COVID-19 pandemic has increased the share of Americans participating in telehealth from 11% in 2019 to 46% today, with healthcare systems reporting a 50 to 175-fold increase in telehealth volume compared to pre-pandemic levels [1]. As the world begins to move from the first wave of reactive care, into a more proactive phase and beyond, virtual care solutions are supporting the recovery of COVID patients as they transition through their care journey, and non-COVID patients as they return to elective surgeries, diagnoses, prevention and treatments that have been put on hold since the onset of the pandemic.

“There is no better time for Philips to team with the ATA. Philips is creating proactive, AI-powered solutions to improve patient monitoring, precision diagnosis, and clinical workflows at every point along the continuum. This directly aligns with our vision for telehealth — to drive the transformation of health by integrating virtual care from the hospital to physician offices and the home,” said Ann Mond Johnson, CEO, the ATA. “Major industry players like Philips joining the ATA reconfirms the importance of telehealth and creates important new opportunities to deliver quality care whenever and wherever it’s needed.”

“Philips has been a leader in telehealth across acute care and post-acute care settings in the hospital and in the home for over three decades, helping health systems deploy and scale telehealth solutions to help improve patient outcomes, enhance patient and staff experience and lower care costs,” said Roy Jakobs, Chief Business Leader Connected Care, member of the Executive Committee at Royal Philips. “Our alignment with ATA will help promote strong  growth and faster adoption of telehealth and policy changes escalated during the COVID crisis as we pivot to innovate ‘virtual first’ strategies to support hospitals, payers, and patients across care settings, including digital health technologies to support healthy living in the home.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version